Initial treatment patterns over time for anaplastic oligodendroglial tumors.
Neuro-oncology., Jun;14(6):761-7 (2012)
Prospective, high-throughput molecular profiling of human gliomas.
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
J. Natl. Cancer Inst., Jan;104(1):42-55 (2012)
Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.
J. Clin. Oncol., Jan;30(3):e30-3 (2012)
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
Cancer Cell., Dec;20(6):810-7 (2011)
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
Neuro-oncology., Feb;14(2):132-44 (2012)
A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.
J. Neuropathol. Exp. Neurol., Feb;70(2):110-5 (2011)
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
Clin. Cancer Res., Oct;15(20):6430-7 (2009)
Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome.
J. Neuropathol. Exp. Neurol., Oct;68(10):1155-65 (2009)
Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations.
Arch. Pathol. Lab. Med., Dec;133(12):1949-53 (2009)
Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression.
Cancer Res., Mar;70(6):2350-8 (2010)
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res., Mar;70(6):2158-64 (2010)
Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors.
Oncogene., Jun;29(22):3185-95 (2010)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.
EMBO Mol Med., May;2(5):146-58 (2010)
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
J. Clin. Oncol., Jun;28(17):2817-23 (2010)
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.
Lancet Neurol., Jul;9(7):717-26 (2010)
Bone involvement predicts poor outcome in atypical meningioma.
J. Neurosurg., Sep;111(3):464-71 (2009)
What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator.
Cell Cycle., Sep;7(18):2833-9 (2008)
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.
Nat. Biotechnol., Jan;27(1):77-83 (2009)
Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
J. Neuropathol. Exp. Neurol., Dec;65(12):1149-56 (2006)